EIF4E and Familial prostate cancer: Earlier, we had reported the potential of VNPP433-3β in treating preclinical models of castration-resistant prostate cancer by promoting degradation of f-AR and preventing phosphorylation of eIF4E by depleting Mnk1/2 [11,30].